Síntese e caracterização de derivados de hemoglobina para aplicação terapêutica / Synthesis and characterization of hemoglobin based oxygen carriers for therapeutic application

A transfusão de sangue é uma intervenção terapêutica capaz de salvar muitas vidas. Entretanto, transfusões também apresentam uma alta gama de possíveis eventos adversos, questões logísticas, econômicas e sociais. Dentre as principais preocupações terapêuticas estão a incompatibilidade (principalmente do sistema ABO), a transmissão de microrganismos patogênicos, os distúrbios imunomodulatórios, as reações hemolíticas, o aumento estatístico do risco de morte proporcional ao volume de sangue infundido, dentre outros. Diversas alternativas às transfusões sanguíneas são propostas na literatura científica, dentre elas o desenvolvimento de transportadores de oxigênio que utilizam a hemoglobina, comumente intitulados substitutos sanguíneos. Neste âmbito, o presente estudo teve como objetivo o desenvolvimento de uma rota de síntese e a síntese de partículas de gelatina contendo hemoglobina polimerizada. Para tanto, realizou-se a síntese do polietileno glicol bis-[succinimidil succinato], extraiu-se e polimerizou-se com glutaraldeído ou polietileno glicol bis-[succinimidil succinato] hemoglobina de sangue bovino e, partículas de gelatina coriácea ou óssea contendo hemoglobina polimerizada foram sintetizadas e caracterizadas. A síntese do polietileno glicol bis-[succinimidil succinato] (SSPEG) foi caracterizada por espectroscopia RAMAN, análise diferencial de calorimetria (DSC) e os resultados obtidos indicaram o sucesso das reações. O produto da reação de polimerização da hemoglobina e albumina com o SSPEG foi verificado por SDS-PAGE e os resultados obtidos indicaram a formação com sucesso de polímeros de alta massa molecular. As partículas contendo hemoglobina polimerizada geradas com gelatina coriácea apresentaram diâmetro hidrodinâmico de 1370 nm, dispersividade de 0,029 e potencial zeta de -36,1 mV. As partículas contendo hemoglobina polimerizada geradas com gelatina óssea apresentaram diâmetro hidrodinâmico de 438 nm, dispersividade de 0,563 e potencial zeta de -24,5 mV. Os resultados obtidos sugerem a aplicabilidade da gelatina coriácea para a produção de partículas contendo hemoglobina polimerizada com possível aplicação como transportador de oxigênio

Blood transfusion is a therapeutic intervention that can save many lives. However, transfusion is also related to several possible adverse therapeutic events and logistic, economic and social concerns. Among the major therapeutic concerns are incompatibility (mainly of the ABO group system), pathogenic microorganisms' transmission, immunomodulatory disturbances, hemolytic reactions, death risk increase that is proportional to the infused volume, among others. Several alternatives to blood transfusion are proposed in the scientific literature. Among them is the development of hemoglobin based oxygen carriers, commonly entitle blood substitutes. To this extent, the present work aimed to develop a synthetic route and to synthesize gelatin particles containing polymerized hemoglobin. To this purpose PEG bis(succinimidyl succinate) was synthesized, bovine hemoglobin was extracted and polymerized with glutaraldehyde or PEG and polyhemoglobin contained particles of gelatin from leather or bones were synthesized and characterized. PEG bis(succinimidyl succinate) synthesis was characterized by RAMAN spectroscopy and by differential scanning calorimetry (DSC) and the obtained results indicated the successful synthesis. The reaction product of the polymerization of hemoglobin or albumin with PEG was verified by SDS-PAGE and the results indicated the successful formation of high molecular mass polymers. The particles generated with leather gelatin and polyhemoglobin had a hydrodynamic diameter of 1370 nm, dispersity of 0.029 and zeta potential of -36.1 mV. Particles generated with bone gelatin and polyhemoglobin had hydrodynamic diameter of 438 nm, dispersity of 0.563 and zeta potential of -24.5 mV. The obtained results suggest the applicability of leather gelatin for the production of polyhemoglobin containing particles aiming to the development of a hemoglobin based oxygen carrier

Tratar, sim; melhorar, não? Análise crítica da fronteira terapia/melhoramento / Treat, yes; improve, no? Critical analysis of the boundary between therapy and improvement / Tratar, sí; mejorar, no? Análisis crítico de la frontera terapia/mejora

Um dos pontos controversos do debate sobre os usos da biotecnologia é a função normativa da fronteira entre terapia e melhoramento. Para quem defende tal fronteira, as intervenções biotecnocientíficas no ser humano têm de restringir-se à terapia, de modo que o melhoramento deve ser proibido. Neste artigo, defendemos que essa fronteira tem importantes imprecisões empíricas e problemas conceituais, sendo normativamente inadequada para justificar a diferença entre o que deve ser prescrito e proscrito. Primeiramente, analisamos a distinção entre normal e anormal, haja vista servir de alicerce a tal fronteira. Em seguida, examinamos a fronteira propriamente dita, a fim de apontar seus problemas. Identificando tais problemas e postulando que a normalidade biológica é desprovida de relevância moral intrínseca, inferimos que não resta claro por que seria moralmente proibido à biotecnologia avançar além da terapia.

One of the controversial points of the debate regarding the uses of biotechnology is the normative function of the boundary between therapy and improvement. For those who defend such a boundary, bio-techno-scientific interventions in human beings must be restricted to therapy, such that improvement must be prohibited. In this paper, we defend the viewpoint that this boundary has important empirical imprecisions and conceptual problems, such that it is normatively inappropriate to justify the difference between what what must be prescribed and proscribed. In the first place, we analyze the distinction between normal and abnormal, in view of the foundations for such a boundary. Next, we examine the boundary per se, in order to point out its problems. Identifying such problems and postulating that biological normality is bereft of intrinsic moral relevance, we infer that it is not clear why it would be morally forbidden for biotechnology to advance beyond therapy.

Uno de los temas polémicos en el debate sobre los usos de la biotecnología es la función normativa de la frontera entre terapia y mejora. Para los que las defienden, las intervenciones biotecnocientíficas sobre el ser humano tienen que restringirse a la terapia, por lo que en la mejora debería estar prohibido. En este artículo, se argumenta que esta frontera tiene importantes imprecisiones empíricas y problemas conceptuales, siendo normativamente inadecuada para justificar la diferencia entre lo que debe ser prescrito y proscrito. En primer lugar, analizamos la distinción entre lo normal y lo anormal, teniendo en cuenta que la misma sirve como base de esa frontera. Después examinamos la frontera misma, con el fin de señalar sus problemas, postulando que la normalidad biológica no tiene una relevancia moral intrínseca y señalando los problemas de esa frontera, deducimos que no queda claro por qué debería estar moralmente prohibido que la biotecnología fuera más allá de la terapia.

Atletas do século XXI: ou das fusões biotecnológicas nos atletas de alto rendimento / Athletes of the XXI century: biotechnological mergers in high performance athletes

Este estudo tem como objetivo discutir as condições contemporâneas vinculadas às biotecnologias e suas relações com o esporte de alto rendimento, em especial, na configuração de um novo tipo de sujeito atleta. Para isso parte de um caso específico do esporte mundial para lançar questões referentes a esta problemática. Assume-se o pressuposto que as bases epistemológicas que organizam o esporte moderno são dualísticas, e acabam por classificar os sujeitos entre atletas normais ou paratletas, sendo, portanto, incapazes de lidar com as transformações hodiernas referentes aos usos de tecnologias para a ampliação das potencialidades humanas. Desse modo, sugere-se, por fim, sobre a possibilidade de novas organizações do contexto esportivo de alto rendimento em âmbito internacional.

This study aims to discuss the contemporary conditions linked to biotechnologies and their relationships with elite sport, in particular, the configuration of a new kind of fellow athlete. For this discussion part of a specific case of the sports world to launch questions regarding this issue.It starts with the assumption that the epistemological foundations that organize modern sport is dualistic, and eventually classify individuals between athletes normal and paratletas, therefore, unable to cope with the changes of our day concerning the uses of technology to expand the potential human.

Este estudio tiene como objetivo discutir las condiciones actuales relacionadas con La biotecnología y su relación con el deporte de élite, em particular, la configuración de un nuevo tipo de deportista. Para esta discusión parte del caso específico del mundo del deporte para lanzar preguntas sobre este tema. Se inicia con la suposición de que los fundamentos epistemológicos que organizan el deporte moderno es dualista, y, finalmente, clasifican a los individuos entre los atletas y paraatletas normales, por lo tanto, incapaz de hacer frente a lós cambios de nuestro tiempo respecto a los usos de La tecnología para ampliar el potencial humano.

Biosafety education relevant to genetically engineered crops for academic and non-academic stakeholders in East Africa

Development and deployment of genetically engineered crops requires effective environmental and food safety assessment capacity. In-country expertise is needed to make locally appropriate decisions. In April 2007, biosafety and biotechnology scientists, regulators, educators, and communicators from Kenya, Tanzania, and Uganda, met to examine the status and needs of biosafety training and educational programs in East Africa. Workshop participants emphasized the importance of developing biosafety capacity within their countries and regionally. Key recommendations included identification of key biosafety curricular components for university students; collaboration among institutions and countries; development of informational materials for non-academic stakeholders and media; and organization of study tours for decision makers. It was emphasized that biosafety knowledge is important for all aspects of environmental health, food safety, and human and animal hygiene. Thus, development of biosafety expertise, policies and procedures can be a stepping stone to facilitate improved biosafety for all aspects of society and the environment.

Assessment of Grenada's capacity to implement the Biosafety Protocol

Grenada's capacity to manage risks posed by living modified organisms (LMOs) is augmented through an Organization of American States funded project called "Biosafety Regulations in Latin America and the Caribbean under the International Biosafety Protocol" The Project is implemented in six countries in Central America and the Caribbean is designed to identify the weaknesses and needs of participating countries in managing of risks posed by LMOs, while also developing a trusting environment for maximizing the benefits of the modern biotechnology industry. The results of the study indicated that the Grenada's legal and institutional framework is not fully conducive for the implementation of the Biosafety Protocol. Specifically, a number of constraints exists which included, limited competencies in risk assessment and management; inadequate legal framework; lack of an established administrative arrangement for risk management; lack of coherence in policies and programs among key implementing agencies; lack of, and/or insignificant awareness among the populace of the implications of biotechnology and inadequate systems of information exchange. To augment national capacity to successfully implement the Cartagena Protocol, training would be needed in the developing relevant legal instruments; conducting risk assessments and developing more effective platforms for information exchange.

The multinational biosafety project of the Organization of American States

The Organization of American States is supporting the project "Biosafety Regulations in Latin America and The Caribbean within the framework of the International Biosafety Protocol". The general objective is to strengthen national skills for the assessment and management of risks of biotechnology food products, and to build up public awareness about their benefits and risks in the participant countries, with the ultimate goal to promote their safe and sustainable use within a protective and trusting environment for the public. The first phase has been focused on the evaluation of the political and regulatory systems in Chile, Peru and Colombia, identification of needs, and development of a series of biosafety seminar-workshops in the three countries, with the participation of distinguished foreign experts. The second phase, which started in March 2003, has been extended to six countries of Central America and The Caribbean. The project is helping to identify the weaknesses and needs for the establishment of the biosafety protocol in each participating country. It has also establish the specific training needs and is given the bases for the design of general outlines of biosafety training plans, which will contribute to an efficient implementation of the International Biosafety Protocol. The project it is also allowing to coordinate actions between the countries for a better implementation of the protocol at a regional level. On the other hand, the project has allowed to assemble, around discussion tables, international experts with the main representatives of regulatory and academic institutions, business enterprises and NGOs, as well as with congressmen in scientific and technological matters and the protection of biodiversity. Thus, the project has permitted the establishment of cooperation linkages and has contributed to reinforce the notion of the importance of biosafety for national development and the preservation of local biodiversity.

O Brasil e os novos desafios da bioética / Brazil and the news aspects of bioethics

O artigo focaliza a bioetica, analisando os principais codigos internacionais e apresentando sucinta revisao da experiencia de alguns paises desenvolvidos nesse campo. O objetivo principal e indicar os aspectos mais relevantes e controvertidos a serem considerados na experiencia brasileira